Bifunctional ShRNAimPDX-1 Therapy Prevents Hypoglycemic Death From Insulinoma in Mice Abstract #502

Introduction: PDX-1 is a novel molecular target for insulinoma. Bi-functional shRNAi platform has been developed that results in a more effective targeted gene knockdown.
Aim(s): Using bi-shRNAimPDX-1 therapy in a mouse model of metastatic insulinoma to determine whether PDX-1 is a therapeutic target for insulinoma.
Materials and methods: Insulinoma (ß TC-6) cell proliferation and insulin secretion in vitro were determined by MTS and ELISA assay after bi-shRNAimPDX-1. In vivo therapy was performed on an i.p. ß TC-6 SCID mouse model with three bi-weekly cycles of iv liposomal(L)- bi-shRNAimPDX-1. Glucose and insulin levels and expression of islet cell PDX-1, insulin, PP levels, apoptosis and cell cycle proteins were determined. Survival analysis was performed using Kaplan-Meier (p<0.05).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr F Charles Brunicardi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2737 Identification of a Novel MAFA Missense Mutation Causing Familial Insulinomatosis
Introduction: Insulinomatosis is a rare pancreatic disease characterized by an adult-onset condition of recurrent hyperinsulinemic hypoglycemia caused by multiple insulin-secreting neuroendocrine tumors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PD. Dr. Christian Fottner
#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dijie Liu
#3013 Structurally-Optimized Peptide VMT-Alpha-NET Enhances the Efficacy of SSTR2-Targeted Alpha-Particle Therapy for Neuroendocrine Tumors
Introduction: 203Pb/212Pb is a promising theranostics pair for SSTR2-targeted alpha-particle therapy for neuroendocrine tumors (NETs). The development of SSTR2-targeted peptides that are optimized for the Pb isotopes has the potential to improve performance.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dongyoul Lee
Authors: Lee D, Li M, Baumhover N, Liu D, ...
#390 An Increasing Incidence of GEP-NETs in Chengdu City with a Population of 14 Million in China
Introduction: The annual incidence of GEP-NETs in China is still unclear. All histopathology and cytopathology reports have yet to be collected in a national archive. No national or regional survey on GEP-NETs has been approved. West China Hospital (WCH), a university hospital located in Chengdu City with a population of 14 million, has established a series of databases in recent years.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Tang Chengwei
Authors: Guo L, Wang C, Liu W, Zhong M, ...
#978 Prognostic Value of Somatostatin Receptor Scintigraphy on High-Grade Neuroendocrine Neoplasms and Impact on the Treatment Decision of Intermediate-Grade Neuroendocrine Neoplasms
Introduction: Somatostatin receptor scintigraphy (SRS) could detect not only somatostatin receptors but also tumor images in patients with neuroendocrine neoplasms (NENs).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Jian Ming Xu
Authors: Jia R, Fu Y L, Lin L, Wang Y, ...